Search

Displaying results 4751 - 4760 of 10000 in total
  1. Drug

    Sitamaquine

    go.drugbank.com/drugs/DB04909
    Investigational

    Sitamaquine (WR-6026) is an orally active 8-aminoquinoline analog in development by the Walter Reed Army Institute, in collaboration with GlaxoSmithKline (formerly SmithKline Beecham), for the potential

  2. Drug

    Olorofim

    go.drugbank.com/drugs/DB15245
    Investigational

    Olorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).

  3. Drug

    Centhaquine

    go.drugbank.com/drugs/DB16122
    Investigational

    Centhaquine is under investigation in clinical trial NCT04045327 (Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock).

  4. Drug

    BRG01

    go.drugbank.com/drugs/DB18173
    Investigational

    BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.[L48111]

  5. Drug

    CTR-107

    go.drugbank.com/drugs/DB18583
    Experimental

    CTR-107 is a synthetic targeted growth factor. It is being investigated for the treatment of familial exudative vitreoretinopathy.

  6. Drug

    Elebsiran

    go.drugbank.com/drugs/DB19018
    Investigational

    Elebsiran is under investigation in clinical trial NCT05461170 (SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.).

  7. Drug

    LS11

    go.drugbank.com/drugs/DB05918
    Investigational

    LS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity.

  8. Drug

    Fludiazepam

    go.drugbank.com/drugs/DB01567
    IllicitInvestigational

    It is a scheduled drug in the U.S., but is approved for use in Japan. … Fludiazepam is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties.

  9. Drug

    LU-31130

    go.drugbank.com/drugs/DB05828
    Experimental

    LU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders. … It acts at the Dopamine D4 receptors in the cortex and has low affinity for D2 receptors, adrenoceptors, muscarinic and histaminergic receptors.

  10. Drug

    Vibriolysin

    go.drugbank.com/drugs/DB05135
    Experimental

    It is a new agent for enzymatic debridement, shown to rapidly and thoroughly hydrolyze burn wound eschar within full-thickness wounds. … Vibriolysin is a proteolytic enzyme secreted by the marine microorganism Vibrio proteolyticus.